Description
IDEXX Laboratories’ $421 Million Cash Flow Powerhouse — But Can Growth Last?
IDEXX Laboratories Inc. reported its third quarter 2026 financial results with a 10% organic revenue growth, driven primarily by its Companion Animal Group (CAG) Diagnostics recurring revenues, which rose 11% organically. This growth was supported by strong international expansion, where CAG Diagnostics grew nearly 14%, alongside a 10% increase in the U.S. The company’s premium instrument placements reached nearly 5,800 units during the quarter, including 1,900 IDEXX InVue Dx analyzers, contributing to increased consumable sales and higher diagnostic utilization per visit despite a modest 1.8% decline in U.S. clinical visits. IDEXX’s global reference labs grew by 10%, bolstered by volume gains from new customer acquisitions and expanded CancerDx panel adoption, now including canine mast cell tumor detection without increasing pricing. Operating margin improved by approximately 60 basis points on a comparable basis, with reported operating margins at 33.



